

Single-cell RNA sequencing reveals the distinctive roles of CD4⁺ and CD8⁺ T cells in autoimmune uveitis

Hao Kang^{1#}, Hongjian Sun^{2,3#}, Yang Yang^{2,3}, Minglei Shu³, Yunbo Wei⁴, Yu Zhang⁴, Di Yu^{2,5*} and Yong Tao^{1*}

1. Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University
2. Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
3. Shandong Artificial Intelligence Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China
4. School of Pharmaceutical Sciences, Laboratory of Immunology for Environment and Health, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China
5. Ian Frazer Centre for Children's Immunotherapy Research, Children's Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane QLD, Australia

Hao Kang and Hongjian Sun contribute equally to this study.

* Di Yu and Yong Tao contribute equally to this study.

Correspondence:

Prof. Yong Tao

Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University;

No. 8, South Road of Worker's Stadium, Chaoyang District, Beijing 100020, China.

Phone: +86-10-85231718.

Fax: +86-10-85231405.

E-mail: taoyong@bjcyh.com

Prof. Di Yu

Frazer Institute, Faculty of Medicine, The University of Queensland.

Translational Research Institute (TRI), 37 Kent Street, Woolloongabba, QLD 4102, Australia.

Phone: +61-07-34436954.

E-mail: di.yu@uq.edu.au

1 **Abstract**

2 Uveitis is a common cause of blindness and classified as infectious or non-infectious types. Non-infectious
3 uveitis is often secondary to systemic autoimmune diseases, with Behçet's disease (BD) and Vogt-Koyanagi-
4 Harada disease (VKHD) as the two most common causes. Uveitis in BD and VKHD often show similar clinical
5 manifestations, but the underlying immunopathogenesis remains unclear. We collected immune cell infiltrates
6 in aqueous humour of BD and VKHD uveitis patients and analysed them by single-cell RNA paired with T cell
7 receptor (TCR) sequencing. T cells were found as the dominant immune cell infiltration. Intriguingly, a majority
8 of CD4⁺ in T cell infiltrates was only observed in VKHD but not in BD. In agreement with this discrepancy
9 between VKHD and BD, T cell clonality analysis and Clonotype Neighbour Graph Analysis (CoNGA) also
10 revealed a selective expansion of pro-inflammatory CD4⁺ T cell clones in VKHD. In contrast, BD showed a
11 selective expansion of pro-inflammatory CD8⁺ T cell clones. Our study reveals distinct immunopathogenesis of
12 uveitis driven by CD4⁺ T cells in VKHD and by CD8⁺ T cells in BD, and therefore suggests differential approaches
13 for their diagnosis and therapy.

14

15 **Keywords:**

16 Uveitis

17 single-cell RNA sequencing

18 Behcet disease

19 Vogt-Koyanagi-Harada disease

20 T cell clonality

21

22 **1. Introduction**

23 Uveitis is an inflammatory disorder of the uveal tract of the eye that can be caused by multiple reasons. This
24 vision-threatening disease can cause serious complications such as visual impairment and blindness in 35% of
25 patients [1]. Uveitis can be divided into infectious and non-infectious types according to its etiology. As a more
26 common type, non-infectious uveitis is often related to autoimmune diseases, such as Behçet's disease (BD)
27 and Vogt-Koyanagi-Harada disease (VKHD). Although BD and VKHD show the characteristics of familial
28 aggregation, they differ in geographical distribution. BD is more prevalent in Asia, the Middle East and the
29 Mediterranean than other regions and is characterised by three main clinical features of nongranulomatous
30 uveitis, oral ulcers and genital ulcers [2]. VKHD is considered to distribute worldwide, with a higher occurrence
31 in people with darker skin [3]. The clinical features of VKHD are bilateral granulomatous pancreatitis, polio, vitiligo,
32 and central nervous system abnormalities [4].

33

34 The immunological pathogenesis of BD and VKHD remains elusive although the dysregulated function of T cells,
35 including cytotoxic CD8⁺ T cells or CD4⁺ T cell subset Th1 and Th17 cells, have been implicated in the
36 development of both BD and VKHD [5, 6]. To gain insight into the immunological pathogenesis of human uveitis,
37 we decided to perform single-cell RNA sequencing (scRNA-seq) of cellular infiltrates in aqueous humour from
38 uveitis patients. Due to the significant involvement of T cells in immunopathogenesis, we included T cell receptor
39 (TCR) sequencing. We discovered that uveitis in VKHD was associated with a strong clonal expansion of
40 effector CD4⁺ T cells expressing pro-inflammatory cytokines *IFNG* and *TNF*. In contrast, uveitis in BD was
41 associated with a selective clonal expansion of effector CD8⁺ T cells expressing cytotoxic molecules *GZMB*
42 and *PRF1*. The different immunopathogenesis of non-infectious uveitis distinctively driven by CD4⁺ T cells in
43 VKHD and CD8⁺ T cells in BD strongly suggests differential approaches for the diagnosis and therapy of uveitis
44 in VKHD and BD.

45

46

47 **2. Material and methods**

48 **2.1 Resource availability**

49 **2.1.1 Lead contact**

50 Further information and requests for resources and reagents should be directed to and will be fulfilled by the
51 corresponding authors Di Yu and Yong Tao.

52 **2.1.2 Data and code availability**

53 The datasets during this study are available at the *Science DataBase*: <https://www.scidb.cn/s/bAF7fe>. Codes
54 are available at <https://github.com/HongjianSun/Uveitis-project>.

55

56 **2.2 Experiment model and subject details**

57 This study was performed at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. The ethics
58 approval was obtained from the Ethics Committee of Beijing Chaoyang Hospital. Written informed consent
59 was obtained from all patients. Two VKHD patients and one BD patient (30-40 years old, > 3 years of disease
60 duration) were enrolled at the Ophthalmology Department of Beijing Chaoyang Hospital affiliated with Capital
61 Medical University. All patients had bilateral or unilateral vision loss and had cataract surgeries.

62

63 **2.3 Method details**

64 **2.3.1 Single-cell collection**

65 Aqueous humour of about 100 μ L was taken from individual patients after an anterior chamber paracentesis
66 (ACP). The ACP was carried out by using a 30-gauge needle, on a 1 mL insulin syringe, via the temporal
67 limbal approach and a rolling technique. Aqueous humour was aspirated and immediately aliquoted into a
68 microfuge tube. All the aqueous humour samples were centrifuged at 800 g for 15 minutes. After removing the
69 supernatant, the cells were suspended in red blood cell lysis buffer (Solarbio) and incubated on ice for 2 min
70 to lyse red blood cells. The pellets were washed twice with PBS.

71 **2.3.2 Single-cell RNA sequencing**

72 10X Genomics Platform was used for single-cell RNA sequencing. Single-cell suspension with gel beads
73 (containing the pre-made 10X primers) and Master Mix together formed Gel Bead-In-Emulsions (GEMs).
74 Cleavage and reverse transcription were performed in GEMs. After cDNA amplification was completed, we
75 performed a quality inspection and finally constructed the library. The Illumina Novaseq 6000 sequencing
76 platform was used for sequencing, obtaining sequencing data, and performing subsequent data analysis.

77

78 Fastq reads were initially filtered using *Trimmomatic*^[7]. Next, we used Feature Counts software to quantify the
79 expression of each gene, and counts were obtained for each sample. In our analysis, a qualified gene
80 expression profile from a single cell should have one or more counts in a sample. The expression level of
81 each gene was converted to a transcript per million (TPM) value. Then, the log-normalized expression values
82 were transformed.

83 **2.3.3 Data processing**

84 *Seurat*^[8] was used for scRNA-seq data processing. *Doubletfinder* R package was used to identify doublets^[9]
85 and 7.5% was removed as the recommendation. Subsequently, cells from three patient samples were
86 integrated using the *IntegrateData* package to eliminate batch effects.

87 **2.3.4 Data analyzing**

88 *The data were normalized and scaled by NormalizeData and ScaleData in Seurat. Unsupervised clustering*
89 *was performed using FindClusters in Seurat by a shared nearest neighbour modularity optimization.*
90 *Differential gene expression analysis was performed using FindMarkers and FindAllMarkers in Seurat with the*
91 *parameter of adjusted P-value threshold<0.05. Trajectory analysis was performed by learn_graph, order_cells*
92 *and plot_cells in Monocle3 R package and based on UMAP reduction method^[10].*

93 **2.3.5 Visualization**

94 *scRNA-seq data were visualized using the dimensionality reduction method of UMAP (Uniform Manifold*
95 *Approximation and Projection). Stacked violin plots were made by a modified function of Vlnplot in Seurat.*
96 *Heat map showing the top 5 highest differential expressed genes in each cluster was made by DoHeatmap*
97 *function.*

98 **2.3.6 Enrichment Analysis**

99 *Gene set enrichment analysis (GSEA) was performed^[11] with gene sets from Molecular Signatures Database*
100 *v7.4. The enrichment scores (ES) for a gene set reflect the extent to which a transcriptome is overrepresented*
101 *at the top or bottom of a sequence list of genes, while Normalized Enrichment Scores (NES) are used for*
102 *comparing the enrichment results through the gene sets. The P-value and the False Discovery Rate (FDR)*
103 *are both parameters indicating the confidence level of gene set enrichment.*

104 **2.3.7 V(D)J sequencing**

105 *V(D)J sequencing were analyzed by CellRanger. The CellRanger VDJ function was used for Contig assembly,*
106 *cross-cell Consensus sequence, CDR3 Clonotype typing of Loupe V(D)J Browser analysis results on TCR*
107 *gene V(D)J region sequences of a single cell. Seurat and scRepertoire^[12] were used to add VDJ sequencing*
108 *data as additional data to merge with single-cell sequencing data.*

109 **2.3.8 Clonotype neighbour graph analysis**

110 *Clonotype neighbour graph analysis(CoNGA) identifies the correlation between T cell gene expression(GEX)*
111 *and TCR sequence by constructing a GEX similarity graph based on the gene expression, and a TCR*

112 sequence similarity graph based on *TCRdist* for each clonotypes' CDR3 sequence, and then find a statistically
113 significant overlap between them. Overlap is assessed on a score that reflects the likelihood of seeing equal
114 or greater overlap by chance, named the CoNGA score. The more the overlap between GEX and TCR graph,
115 the smaller the CONGA score will be. Then, Clonotypes with CoNGA scores below a threshold are grouped
116 based on shared GEX and TCR cluster assignments into CoNGA clusters. Clonotypes within each CoNGA
117 cluster carry their initial GEX and TCR cluster identities, which are combined together and used as a group ID
118 for the CoNGA cluster.

119 **2.3.9 Statistical analysis**

120 The *Circos*^[13] was created to illustrate the correlations between two groups. Pie charts and histograms were
121 made by *Prism V9* and *Microsoft Excel*.

122

123 **3. Result**

124 **3.1 T cells are the dominant immune cell type infiltrating in uveitis lesions in both BD and** 125 **VKHD**

126 Three uveitis patients at the age of 30-40 years old, one diagnosed with BD and two diagnosed with chronic
127 recurrent VKHD volunteered to participate in this study. They all had decreased vision and had cataract surgery
128 more than two years before the sample collection in 2019 (**Fig. 1a**). We choose 5' whole transcriptome gene
129 expression (10×Genomics) to gain the information for both transcriptomes and paired full-length TCR for
130 immune repertoire analysis. The library preparation, sequencing, read mapping, gene count normalization and
131 doublet removal were conducted using a standard pipeline (**Fig. 1b**)^[14].

132

133 After the integration of data from three samples, a total of 17,961 cells underwent the downstream analysis.
134 After doublet removing and data integration, the single cells were visualized by UMAP in two-dimensional space.
135 Using KNN method for clustering, the immune cells in uveitis were classified into 12 clusters (**Fig. 1c, S1a**).
136 *CD3*⁺ T cells (cluster 0-4, 6, 8-11) were the dominant immune cell population (11,983 cells) accounting for 44.6%
137 (856/1919), 72.7% (4557/6268) and 67.2% (6570/9774) of total cells from BD, VKHD1 and VKHD2 patients.
138 *CD19*⁺ B cells (cluster 5) were approximately 10% in all samples. Interestingly, *CD14*⁺ monocytes (cluster 7)
139 showed a higher percentage in BD (20.6%) than those in VKHD (VKHD1: 4.0%; VKHD2: 0.4%) (**Fig. 1d, S1b**).

140

141 **3.2 T cells in uveitis lesions are composed of distinct functional subsets**

142 We then focused on T cells as the major immune cell population and identified 11 clusters (**Fig. 2a**), which were
143 predominantly $\alpha\beta$ T cells (**Fig. 2b**). We didn't observe significant enrichment of genes for TCR δ and γ ,
144 *V α 24/V β 11* associated with natural killer T (NKT) cells, or *V α 2/V α 7/V β 2/13* associated with mucosal-associated

145 invariant T (MAIT) cells in particular subsets ^[15, 16] (**Fig.S2a**). Clusters 1, 2, 4, 5, 7, 8, 9 and 10 expressed *CD4*
146 while clusters 3 and 6 expressed *CD8A* and *CD8B*. Cluster 0 are *CD4*⁻*CD8*⁻ (double negative, DN) T cells, a
147 population which is rare in a normal condition but expands in inflammation and autoimmune diseases ^[17] (**Fig.**
148 **2b**). Notably, VKHD samples showed *CD4*⁺ T cells as the clear majority (VKHD1: 68%; VKHD2: 57%) with
149 *CD4*/*CD8* ratios as 4.3 and 2.6. In contrast, *CD4*⁺ and *CD8*⁺ T cell numbers were largely comparable in BD (**Fig.**
150 **2c**), with the *CD4*/*CD8* ratio of 1.4. This difference suggests a potential difference in immunopathogenesis of
151 non-infectious uveitis of BD and VKHD.

152

153 Using differential gene expressions (DGE) among different clusters (**Fig. 2d**), we annotated their states and
154 functions. *CD4*⁻*CD8*⁻ T cells (Cluster 0, C0) were resting T cells with low expression of effector molecules (**Fig.**
155 **2e**). Within the *CD8*⁺ T cells, C6 was a central memory population with the higher expression of the chemotaxis
156 and trafficking receptor genes *CCR7* and *SELL* (encoding *CD62L*) for recirculation, while C3 was the effector
157 subset with significant expression of effector function genes for C-C chemokine ligands (*CCL5*), granzymes
158 (*GZMA* and *GZMB*) and perforin (*PRF1*) (**Fig. 2e**). Gene Set Enrichment Analysis (GSEA) demonstrated that
159 DGE between C3 and C6 was positively associated with gene expression in effector *CD8*⁺ T cells as compared
160 to memory or naïve *CD8*⁺ T cells in the model of acute infection (**Fig. S2b**). The trajectory analysis suggested
161 that *CD8*⁺ T cells underwent a relatively linear differentiation with a likely progression from memory to effector
162 (**Fig. s2c**).

163

164 Within the *CD4*⁺ T cells, C8 showed a high expression of the proliferation marker *MKI67* (encoding *KI-67*). Such
165 a highly proliferative population also expressed *CD38* and proinflammatory effector genes *IFNG* and *TNF* (**Fig.**
166 **2e**), which were recently shown to be correlated with disease severity in COVID-19 ^[18]. Compared to C8, C4
167 expresses higher amounts of *IFNG* and *TNF*. They reduced proliferation but underwent terminal differentiation
168 with an upregulation of *PDCD1* (encoding *PD-1*). Notably, C1 showed the highest levels of *PDCD1* and *CTLA4*,
169 suggesting an exhaustion state with the downregulation of effector molecules (**Fig. 2e**). DGE between C4 and
170 C1 was enriched with the signatures of T cell exhaustion by GSEA (**Fig. S2d**).

171

172 C9 is tissue-residential memory T (*T_{RM}*) cells with the expression of chemokine receptor and integrin *CXCR6*
173 and *IGTB1*. C2 and C5 express a high level of inhibitory receptor *KLRB1* (encoding *CD161*). C10 upregulated
174 the initiator of the complement classical pathway *C1QA* and *C1QB*, which were reported to restrain autoimmune
175 response ^[19]. C7 was regulatory T (*T_{REG}*) cells with the high expression of markers *CTLA4*, *FOXP3* and *IL2RA*
176 (encoding *CD25*) (**Fig. 2e**). The trajectory analysis of conventional *CD4*⁺ T cells (C8, *CD4*, C1, C9, C2, C5 and
177 C10) suggested that recently activated and proliferating *CD4*⁺ T cells (C8) may further differentiate and branch
178 into effector (C4), exhausted (C1) and *KLRB1*⁺ (C2 and C5) clusters (**Fig. S2e**).

179

180 With the annotation of T cell functional clusters, we noticed major differences in the frequencies of *CD4*⁺ and
181 *CD8*⁺ T cell clusters between VKHD and BD whereas the frequencies of DN T cells were largely comparable
182 among these patients. In agreement with the selectively high *CD4*/*CD8* ratios in VKHD patients, effector (C4)

183 and exhausted (C1) CD4⁺ T cells were in much larger amounts in VKHD but not in BD patients. In contrast,
184 effector (C3) CD8⁺ T cells were particularly expanded in the BD patient (**Fig. 2f**). These results suggest a notion
185 that uveitis in VKHD and BD is preferentially associated with effector CD4⁺ T cells and effector CD8⁺ T cells,
186 respectively.

187 188 **3.3 Divergent T cell clonal expansion in BD and VKHD uveitis**

189 The antigen is recognised by a specific TCR sequence and its stimulation critically drives T cell proliferation and
190 functional differentiation. We then analysed TCR sequences of T cells in all three patient samples, with an
191 emphasis on clonality by quantifying the frequencies of T cells with a common CDR3 sequence. According to
192 the percentages of the T cell numbers of each T cell clone in the total T cells from a given sample, significantly
193 expanded clones (>0.2% of total T cells) were classified into three groups: Large (> 5% of total T cells), medium
194 (1~5%), small (0.2-1%) clonotypes. Notably, large clonal types are enriched in effector CD8⁺ T cells (C3) and
195 effector (C4) and exhausted (C1) CD4⁺ T cells (**Fig. 3a**), indicating that effector T cells-mediated inflammation
196 in uveitis is driven by antigen stimulation. Intriguingly, there was no large or medium clonal expansion for Treg
197 cells (C7).

198
199 A total of 13 large and medium clonotypes (>1% of total T cells) were detected in VKHD and BD samples,
200 including 5 in VKHD1, 6 in VKHD2 and 2 in BD (**Fig. 3b, S3**). There were no identical CDR3 sequences among
201 clonotypes from different samples. We then generated topographic maps to visualise the distribution of cells
202 from large and medium clonotypes in each sample. Furthermore, to understand the relationship between clonal
203 expansion and functional T cell clusters, we calculated the frequencies of large, medium and small clonotypes
204 in each functional T cell cluster and also the frequencies of each cluster in large, medium or small clonotypes.

205
206 In VKHD, T cell clonal expansions were centred by effector (C4) and exhausted (C1) CD4⁺ T cells (left panels,
207 **Fig. 3c**). Indeed, effector (C4) and exhausted (C1) CD4⁺ T cells accounted for about 70% large and medium
208 clonotypes (middle panels, **Fig. 3c**). Conversely, large and medium clonotypes only accounted for 10-20% of
209 total effector (C4) and exhausted (C1) CD4⁺ T cells (right panels, **Fig. 3c**). The inclusion of small clonotypes
210 could increase the frequencies to about 50%. These results suggest a key role of (auto)antigen-driven CD4⁺ T
211 cell activation in the immunopathogenesis in VKHD.

212
213 In BD, T cell clonal expansion was exclusively in effector (C3) CD8⁺ T cells (left panel, **Fig. 3d**). Strikingly,
214 effector (C3) CD8⁺ T cells accounted for about 80% of large clonotypes (middle panel, **Fig. 3d**). Conversely,
215 large clonotypes accounted for >40% of total effector (C3) CD8⁺ T cells (right panel, **Fig. 3d**). These results
216 strongly argue an essential role of (auto)antigen-driven CD8⁺ T cell activation in the immunopathogenesis in BD,
217 which is distinct from VKHD.

218
219 In both VKHD and BD, T_{REG} cells (C7) only accounted for a small fraction of T cells (3-5%, **Fig. 2f**). A striking
220 observation was that T_{REG} cells (C7) underwent the least clonal expansion in both VKHD and BD, suggesting

221 that insufficient expansion of T_{REG} cells might posit in the root of losing immune tolerance in non-infectious
222 uveitis. Our previous clinical trials of low-dose IL-2 therapy in systems lupus erythematosus and Sjogren's
223 syndrome have demonstrated that it could enhance antigen-independent expansion of T_{REG} cells ^[20, 21], thus
224 providing a strategy to improve the poor clonal expansion of T_{REG} cells in non-infectious uveitis.

225

226 **3.4 CoNGA identifies similar clonotypes with minor contribution to the inflammation in uveitis**

227 About 50% of effector (C4) and exhausted (C1) CD4⁺ T cells in VKHD (right panels, **Fig. 3c**) and about 40% of
228 effector (C3) CD8⁺ T cells in BD (right panels, **Fig. 3d**) didn't carry significantly expanded TCR sequences, e.g.
229 not in large, medium or small clonotypes. This may be explained by TCR-independent activation of T cells, a
230 phenomenon termed 'bystander activation' that has been reported in infection and inflammation ^[22]. An
231 alternative explanation could be that (auto)antigen can activate T cells with similar TCR but such related
232 clonotypes were not identified by identical CDR3 sequences. To test the latter possibility, we applied Clonotype
233 neighbour graph analysis (*CoNGA*), which is a latest method for identifying related clonotypes with similarities
234 in both gene expression and TCR sequences ^[23] (**Fig. 4a**).

235

236 We performed *CoNGA* on merged single-cell and TCR sequence data. Noticeably, *CoNGA* transformed the
237 scRNA-seq and TCR sequence data and reduced multiple T cells with identical TCR to one cell for *CoNGA* plots
238 ^[23]. *CoNGA* identified four *CoNGA* clonotypes/clusters (similar gene expression and similar TCR sequences)
239 (**Fig. 4b**). Intriguingly, *CoNGA* clonotypes/clusters 0-10 (GEX Cluster0-TCR Cluster10, **Fig. 4b**) and 0-3 were
240 composed of cells from both VKHD1 and VKHD2. *CoNGA* clonotypes/clusters 4-2 and 5-7 were composed of
241 cells solely from VKHD1 and BD respectively (**Fig. 4c**). We labelled cells identified by *CoNGA*
242 clonotypes/clusters in the UMAP plot and found the majority of such cells were effector (C4) and exhausted (C1)
243 CD4⁺ T cells, or effector (C3) CD8⁺ T cells, except for some cells in the *CoNGA* clonotype/cluster 5-7 belowed
244 to DN (C0) T cells (**Fig. 4d**).

245

246 These results suggest that (auto)antigen can activate CD4⁺ or CD8⁺ T cells with similar rather than identical
247 TCR to generate effector cells. We next calculated the contribution of 'similar' clonotypes and they only very
248 modestly increased the clonotype frequencies in clusters (**Fig. S4**). Taken together, 'similar' clonotypes can
249 contribute to the immunopathogenesis of uveitis, but 'identical' clonotypes appeared to be the major drivers.

250

251

252 **4. Discussion**

253 Ocular immune privilege has been supported by multiple facets of evidence ^[24]. The prominent presence of T
254 cell infiltration in non-infectious uveitis suggests they may play a significant role in the immunopathogenesis,
255 which is also supported by results from mouse models of experimental autoimmune uveitis and clinical benefits
256 observed from T cell-targeting therapies ^[25]. However, the results from human studies were not always
257 consistent, at least partially due to the heterogeneity nature of non-infectious uveitis. Systems immunology
258 approaches have been taken to stratify uveitis patients, such as by peripheral blood transcriptomic analyses ^[26].

259 The latest advancement of scRNA-seq technology allows us to directly investigate immune responses in the
260 ocular microenvironment, thus providing unprecedented opportunities to understand both immunopathogenesis
261 and the heterogeneity among patients [27, 28].

262

263 Our scRNA-seq of cells in aqueous humour from non-infectious uveitis patients confirmed a dominant presence
264 and pro-inflammatory phenotypes of T cells. More importantly, the analyses revealed that T cell phenotypes in
265 VKHD-associated uveitis were different from those in BD-associated uveitis. Uveitis in VKHD patients showed
266 the dominant role of clonally expanded effector CD4⁺ T cells expressing *IFNG* and *TNF*. In contrast, uveitis in
267 the BD patient had few of these effector CD4⁺ T cells but was characterised by clonally expanded effector CD8⁺
268 T cells expressing *CCL5*, *GZMA*, *GZMB* and *PRF1*.

269

270 The results strongly suggest the distinctive roles of CD4⁺ and CD8⁺ T cells in the pathogenesis of non-infectious
271 uveitis in VKHD and BD. Such a notion is supported by genetic studies including genome-wide association
272 studies (GWAS). In multiple populations, BD was found associated with MHC class I-specific allele HLA-B*51,
273 while VKHD was associated with MHC class II-specific alleles HLA-DR4/HLA-DRB1 [29, 30]. The important
274 question following our study is what (auto)antigens drive the clonal expansion of effector CD4⁺ T cells in VKHD
275 and the clonal expansion of effector CD8⁺ T cells in BD, with ocular antigens as candidates. If such antigen can
276 be identified to specifically activate individual patient's T cell clones, the therapy to specifically induce the
277 tolerance to the antigen will be promising as the precedent clinical trial [31]. However, given that identical
278 clonotypes and similar clonotypes identified by CoNGA accounted for only half of effector CD4⁺ and CD8⁺ T
279 cells, our study suggests TCR-independent 'bystander' activation of T cells in both VKHD and BD-associated
280 uveitis. This should be taken into account for designing therapeutic strategies for non-infectious uveitis. Another
281 potential application derived from our study is to combine immunological signatures with genetic signatures to
282 stratify patients for therapies that selectively target CD4⁺ or CD8⁺ T cells.

283

284 Similar to two recent scRNA-seq studies of aqueous immune cells from 4-5 samples [27, 28], a major limitation of
285 our study was the limitation of sample numbers. Our results should be validated using a larger sample number.
286 Another limitation was the lack of paired blood samples. If the signatures of expanded T cell clonotypes could
287 be detected in blood samples, a strategy could be considered to monitor blood samples rather than invasive
288 ocular sampling.

289

290 **Acknowledgements**

291 This work was supported by the National Natural Science Foundation of China (Grant No.81900849, 82070948,
292 82071792), Beijing Talent Project (No.2020027), Shunyi District "Beijing Science and technology achievements
293 transformation coordination and service platform" construction fund (SYGX202010) and Capital Health

294 Development Scientific Research Project Grant (to Y.T.). Natural Science Foundation of Shandong Province
295 (Major Basic Program, ZR2020ZD41 to M.S.). Australian National Health Medical Research Council Investigator
296 Fellowship (GNT2009554) and Bellberry-Viertel Senior Medical Research Fellowship (to D.Y.) and The
297 University of Queensland Postgraduate Scholarship (to H.S.).

298

299 **Author Contributions**

300 **Hao Kang:** Methodology, Resources, Writing – Original Draft **Hongjian Sun:** Methodology, Software, Formal
301 Analysis, Writing – Original Draft, Visualization **Yang Yang:** Methodology **Minglei Shu:** Supervision **Yunbo Wei:**
302 Methodology **Yu Zhang:** Supervision **Di Yu:** Conceptualization, Writing – Review & Editing, Supervision,
303 Funding Acquisition **Yong Tao:** Conceptualization, Writing – Review & Editing, Supervision, Funding Acquisition

304

305 **Additional Information**

306 Supplementary material can be accessed through the online version of this article.

307

308 **Competing interests**

309 The authors declare no competing interest.

310

311

312 **Figure legends**

313 **Figure 1. T cells are the dominant immune cell type infiltrating in lesions of non-infectious**
314 **uveitis**

315 **(a)** Demographic and clinical information of VKHD and BD patients. **(b)** Schematics of the research design. **(c)**
316 UMAP plot showing unsupervised clustering of cells in aqueous humour analysed by scRNA-seq (pooled data
317 from three patients); subgraphs showing the gene expression of *CD3*, *CD14* and *CD19*. **(d)** UMAP plots showing
318 single cells and clusters in samples from each patient sample (left panels) and frequencies of CD3⁺ T cells,
319 CD19⁺ B cells and CD14⁺ monocytes (right panels).

320

321 **Figure 2. T cell functional subsets in non-infectious uveitis differ between VKHD and BD.**

322 **(a)** UMAP plot showing unsupervised clustering of CD3⁺ T cells (pooled from three patients); subgraphs showing
323 the gene expression of *CD4* and *CD8* (both *CD8A* and *CD8B*). **(b)** Violin plots showing the expression of
324 indicated TCR and co-receptor genes in each cluster. **(c)** UMAP plots showing single cells and clusters in
325 samples from each patient (left panels) and frequencies of CD4⁺ T cells, CD8⁺ T cells and CD4⁺CD8⁻ (double
326 negative, DN) T cells (right panels). **(d)** Heatmap showing top 5 differentially expressed genes in each cluster.
327 **(e)** Violin plots of key marker genes for annotating clusters, with the annotation of clusters to the left. **(f)** Pie
328 charts showing the frequencies of each T cell cluster in samples from individual patients.

329

330 **Figure 3. Divergent T cell clonal expansion in BD and VKHD uveitis.**

331 **(a)** UMAP plots visualising T cell clonal expansion (pooled data from three patients). *Large*: clonotypes > 5 %
332 of total T cells from the same sample; *Medium*: clonotypes 1-5 % of total T cells from the same sample. *Small*:
333 0.2-1 % of total T cells from the same sample. **(b)** Treemap plots showing the frequencies of large and medium
334 clonotypes (>1%) in each patient sample. **(c, d)** Contour plots overlaid with UMAP plots showing the
335 distribution of T cells in large and medium clonotypes (left), frequencies of T cell clusters in each category of
336 significantly expanded clonotypes (middle) and frequencies of significantly expanded clonotypes in each T cell
337 cluster (right) for VKHD (c) and BD (d) patients. N.A., not available.

338

339 **Figure 4. Similar T cell clonotypes in non-infectious uveitis.**

340 **(a)** Schematics of clonotype neighbour graph analysis (CoNGA). **(b)** (Top) CoNGA graph-graph relationship
341 plots showing GEX (gene expression) & TCR in pooled data from three patients and unveiling clonotype clusters
342 with similar GEX and TCR. Each dot represents one clonotype. The GEX plot was generated from the gene
343 expression of representative cells from each clonotype. The TCR plot was generated from the TCR distance for
344 each clonotype. (Middle), the expression of feature genes. (Bottom), DEG and TCR sequence logos showing V
345 and J gene usage and CDR3 sequences. DEG and TCR sequence logos are scaled by the adjusted P value of
346 the associations. DEGs with fold-changes less than 2 are shown in grey. **(c)** Table showing the numbers of T
347 cells belonging to the four biggest CONGA clusters. The CoNGA cluster name was based on its GEX (left) and
348 TCR (right) clusters with a dash in the middle. **(d)** UMAP plots showing T cells identified in the top 4 biggest


349 CoNGA clusters in each patient sample. T cells belonging to individual CoNGA clusters were highlighted in
350 different colours.







351 References


- 352 [1] L. Gamalero, G. Simonini, G. Ferrara, S. Polizzi, T. Giani, R. Cimaz. Evidence-Based Treatment for Uveitis.
353 *Isr Med Assoc J*, 2019;21:475-9.
- 354 [2] H. Yazici, E. Seyahi, G. Hatemi, Y. Yazici. Behcet syndrome: a contemporary view. *Nat Rev Rheumatol*,
355 2018;14:107-19.
- 356 [3] Y. R. Hsu, J. C. Huang, Y. Tao, T. Kaburaki, C. S. Lee, T. C. Lin *et al*. Noninfectious uveitis in the Asia-Pacific
357 region. *Eye (Lond)*, 2019;33:66-77.
- 358 [4] P. Yang, S. Liu, Z. Zhong, L. Du, Z. Ye, W. Zhou *et al*. Comparison of Clinical Features and Visual Outcome
359 between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
360 *Ophthalmology*, 2019;126:1297-305.
- 361 [5] L. Du, A. Kijlstra, P. Yang. Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis
362 and treatment. *Progress in Retinal and Eye Research*, 2016;52:84-111.
- 363 [6] B. Tong, X. Liu, J. Xiao, G. Su. Immunopathogenesis of Behcet's Disease. *Frontiers in Immunology*,
364 2019;10.
- 365 [7] A. M. Bolger, M. Lohse, B. Usadel. Trimmomatic: a flexible trimmer for Illumina sequence data.
366 *Bioinformatics (Oxford, England)*, 2014;30:2114-20.
- 367 [8] Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck, S. Zheng, A. Butler *et al*. Integrated analysis of
368 multimodal single-cell data. *bioRxiv*, 2020:2020.10.12.335331.
- 369 [9] C. S. McGinnis, L. M. Murrow, Z. J. Gartner. DoubletFinder: Doublet Detection in Single-Cell RNA
370 Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst*, 2019;8:329-+.
- 371 [10] C. Trapnell, D. Cacchiarelli, J. Grimsby, P. Pokharel, S. Li, M. Morse *et al*. The dynamics and regulators of
372 cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol*, 2014;32:381-
373 6.
- 374 [11] A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette *et al*. Gene set
375 enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles.
376 *Proc Natl Acad Sci U S A*, 2005;102:15545-50.
- 377 [12] N. Borcharding, N. L. Bormann, G. Kraus. scRepertoire: An R-based toolkit for single-cell immune
378 receptor analysis. *F1000Res*, 2020;9:47.
- 379 [13] M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman *et al*. Circos: an information
380 aesthetic for comparative genomics. *Genome Res*, 2009;19:1639-45.
- 381 [14] T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck *et al*. Comprehensive Integration
382 of Single-Cell Data. *Cell*, 2019;177:1888-+.
- 383 [15] D. G. Pellicci, H.-F. Koay, S. P. Berzins. Thymic development of unconventional T cells: how NKT cells,
384 MAIT cells and $\gamma\delta$ T cells emerge. *Nature Reviews Immunology*, 2020;20:756-70.
- 385 [16] H. Y. Greenaway, B. Ng, D. A. Price, D. C. Douek, M. P. Davenport, V. Venturi. NKT and MAIT invariant
386 TCR α sequences can be produced efficiently by VJ gene recombination. *Immunobiology*, 2013;218:213-
387 24.
- 388 [17] D. Brandt, C. M. Hedrich. TCR $\alpha\beta$ (+)CD3(+)CD4(-)CD8(-) (double negative) T cells in autoimmunity.
389 *Autoimmun Rev*, 2018;17:422-30.
- 390 [18] Z. Chen, E. John Wherry. T cell responses in patients with COVID-19. *Nature Reviews Immunology*,
391 2020;20:529-36.



- 392 [19] G. S. Ling, G. Crawford, N. Buang, I. Bartok, K. Tian, N. M. Thielens *et al.* C1q restrains autoimmunity and
393 viral infection by regulating CD8(+) T cell metabolism. *Science*, 2018;360:558-63.
- 394 [20] J. He, X. Zhang, Y. Wei, X. Sun, Y. Chen, J. Deng *et al.* Low-dose interleukin-2 treatment selectively
395 modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. *Nat Med*, 2016;22:991-3.
- 396 [21] J. He, R. Zhang, M. Shao, X. Zhao, M. Miao, J. Chen *et al.* Efficacy and safety of low-dose IL-2 in the
397 treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. *Ann*
398 *Rheum Dis*, 2020;79:141-9.
- 399 [22] C. H. Shim, S. Cho, Y. M. Shin, J. M. Choi. Emerging role of bystander T cell activation in autoimmune
400 diseases. *BMB Rep*, 2022;55:57-64.
- 401 [23] S. A. Schattgen, K. Guion, J. C. Crawford, A. Souquette, A. M. Barrio, M. J. T. Stubbington *et al.* Integrating
402 T cell receptor sequences and transcriptional profiles by clonotype neighbor graph analysis (CoNGA). *Nat*
403 *Biotechnol*, 2022;40:54-63.
- 404 [24] A. W. Taylor. Ocular immune privilege. *Eye*, 2009;23:1885-9.
- 405 [25] V. L. Perez, R. R. Caspi. Immune mechanisms in inflammatory and degenerative eye disease. *Trends*
406 *Immunol*, 2015;36:354-63.
- 407 [26] J. T. Rosenbaum, C. A. Harrington, R. P. Searles, S. S. Fei, A. Zaki, S. Arepalli *et al.* Identifying RNA
408 Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis. *Am J Ophthalmol*,
409 2021;226:226-34.
- 410 [27] M. Paley, L. M. Hassman, E. Esaulova, G. L. Paley, J. Laurent, L. Springer *et al.* Highly expanded clones
411 representing different lymphocyte lineages are present in individual patients with granulomatous uveitis.
412 *Investigative Ophthalmology & Visual Science*, 2020;61:3661-.
- 413 [28] M. Kasper, M. Heming, D. Schafflick, X. Li, T. Lautwein, M. Meyer Zu Horste *et al.* Intraocular dendritic cells
414 characterize HLA-B27-associated acute anterior uveitis. *Elife*, 2021;10.
- 415 [29] M. Takeuchi, N. Mizuki, S. Ohno. Pathogenesis of Non-Infectious Uveitis Elucidated by Recent Genetic
416 Findings. *Frontiers in Immunology*, 2021;12.
- 417 [30] X. F. Huang, M. A. Brown. Progress in the genetics of uveitis. *Genes Immun*, 2022;23:57-65.
- 418 [31] R. B. Nussenblatt, I. Gery, H. L. Weiner, F. L. Ferris, J. Shiloach, N. Remaley *et al.* Treatment of uveitis by
419 oral administration of retinal antigens: results of a phase I/II randomized masked trial. *Am J Ophthalmol*,
420 1997;123:583-92.
- 421

Patient	VKHD1	VKHD2	BD
Age range at sample collection	31-35	36-40	36-40
Gender	female	male	female
Year range for Onset of disease	2015-2019	2005-2009	2015-2019
Sample collection	2019	2019	2019
Ocular Symptom	Decreased vision in bilateral eyes with accompanying blurred vision	Decreased vision in bilateral eyes	Decreased vision in left eye with accompanying red eye
Visual acuity	20/125 OD and 20/50 OS; Bilateral recurrent anterior uveitis (Mutton fat keratic precipitates, aqueoue flare 2+ and anterior chamber cells 3+ OU);	20/320 OD and 20/30 OS Bilateral recurrent anterior uveitis (Mutton fat keratic precipitates, aqueoue flare + and anterior chamber cells 2+ OU);	No light perception OD and 20/32 OS Bilateral recurrent anterior uveitis (fine, non-pigmented keratic precipitates OD and no KP was observed in OS, aqueoue flare 2+ and anterior chamber cells 3+ OU);
Ophthalmic Examination	Sunset glow fundus, Dalen-Fuchs nodules and retinal pigment epithelium clumping and migration.	Sunset glow fundus.	Optic atrophy, vascular occlusion and gliotic sheathing in OD; retinal vasculitis and retinal oedema in OS.
Surgery	Cataract surgery in bilateral eyes were done.	Cataract surgery in bilateral eyes were done.	Complicated cataract was observed in left eye, and cataract surgery in right eyes were done.
Systemic symptoms	Headache, tinnitus, neck stiffness, hypoacusis, alopecia and poliosis	Headache	Recurrent oral ulcerations, recurrent genital ulcerations and erythema nodosum









c

CONGA cluster (GEX-TCR)	BD T Cells (number)	VKHD1 T Cells (number)	VKHD2 T Cells (number)
0-10	0	21	5
0-3	0	9	5
4-2	0	18	0
5-7	15	0	0

